Y-box结合蛋白-1与增殖细胞核抗原在胃癌组织的表达及与其临床病理特征的相关性

Expression of Y-box Binding Protein-1 and Proliferating Cell Nuclear Antigen in Gastric Carcinoma and Its Correlation with Clinicopathological Features

目的探讨Y-box结合蛋白-1(YB-1)与增殖细胞核抗原(PCNA)在胃癌组织中的表达及其与临床病理特征的相关性。方法采用免疫组化法检测并比较116例胃癌组织(实验组)以及20例癌旁组织(对照组)中YB-1和PCNA的表达,并分析YB-1和PCNA表达与其临床病理特征的相关性。结果实验组YB-1表达阳性81例(69. 83%),PCNA表达阳性72例(62. 07%),另外对照组中YB-1表达阳性4例(20. 00%),PCNA表达阳性3例(15. 00%),2组间YB-1、PCNA的阳性表达差异均有统计学意义(P <0. 01)。胃癌组织中YB-1和PCNA阳性表达与患者年龄、性别无关(P>0. 05),与AJCC分期、分化程度、淋巴结转移及肌层浸润深度有相关性(P <0. 01)。经Spearman相关分析结果显示:YB-1表达与PCNA表达呈正相关性(γ=0. 478,P <0. 05)。结论 YB-1和PCNA均可作为胃癌的肿瘤标志物,联合检测可为胃癌的早期诊断、病理分级提供重要参考依据,也为临床抗肿瘤治疗提供新方向。

Objective To investigate the expression of Y-box binding protein-1 （YB-1） and proliferating cell nuclear antigen （PCNA） in gastric carcinoma and its correlation with clinicopathological features. Methods Immunohistochemistry was used to detect the expression of YB-1 and PCNA in 116 cases of gastric cancer （experimental group） and 20 cases of normal tissues （control group）,and correlation analysis of YB-1 and PCNA expression with clinicopathological features. Results There were 81 cases （69.83%） of positive expression of YB-1 in the experimental group and 72 cases （62.07%） in PCNA expression,4 cases （20.00%） and 3 cases （15.00%） in the control group,the positive expression of YB-1 and PCNA in the 2 groups was statistically significant （ P〈0.01）.The positive expression of YB-1 and PCNA in gastric carcinoma was not correlated with age and sex （ P〉0.05）,which was correlated with AJCC stage,differentiation degree,lymph node metastasis and depth of myometrial invasion （ P〈0.01）.The results of Spearman correlation analysis showed that YB-1 expression was positively correlated with PCNA expression （ γ =0.478, P〈0.05）. Conclusion YB-1 and PCNA can be used as tumor markers of gastric cancer.Combined detection can provide an important reference for the early diagnosis,pathological grade and prognosis of gastric cancer,and also provide a new direction for clinical anti-tumor therapy.